Apixaban reduces VTE recurrence long term

In this large trial of patients with VTE who had already completed 6-12 months of anticoagulation, they were randomized to 12 additional months of apixaban (5 or 10mg bid) versus placebo. Recurrent VTE occurred in 9% of the placebo group, versus 2% of each of the treatment groups. Bleeding occurred in <0.5% of each group. Long term apixaban is effective and safe for reducing recurrent VTE (abstract).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment